Ablynx's AbbVie-Partnered Lupus Candidate Hits End Of Road

 
• By Lucie Ellis-Taitt

Ablynx's IL-6 inhibitor has reached the end of the road in lupus; failure of the Phase II STEADY trial is unlikely to affect the biotech's acquisition deal with Sanofi but its development partner AbbVie is expected to dump the drug.  

Baseball
Swing and miss: Ablynx's vobarilizumab strikes out in lupus • Source: Shutterstock

More from Immunological

More from Therapy Areas